Relationship of soluble fas with body mass index in healthy Japanese adults.

Recent studies have linked elevated serum sFas levels to atherosclerotic disease among patients. Confirming an association between obesity and serum sFas levels in healthy subjects would facilitate our understanding of obesity and its related disorders. We therefore analyzed serum sFas levels of 8,541 subjects selected as controls for a nested case-control study within the JACC Study. Body mass index (BMI) was calculated as the indicator of obesity based on self-reported height and weight. We found a statistically significant positive association between serum sFas levels and BMI among our apparently healthy subjects. Our result suggests that serum sFas rises to down-regulate increased apoptosis in atherogenesis processes caused by obesity.

[1]  S. Kim,et al.  Relationships of soluble APO-1 (Fas/CD95) concentrations, obesity, and serum lipid parameters in healthy adults. , 2005, Annals of clinical and laboratory science.

[2]  S. Uckan,et al.  Cigarette smoking and apoptosis. , 2005, Journal of periodontology.

[3]  A. Tamakoshi,et al.  Profile of the JACC Study , 2005, Journal of epidemiology.

[4]  A. Tamakoshi,et al.  Stability of Frozen Serum Levels of Insulin-like Growth Factor-I, Insulin-like Growth Factor-II, Insulin-like Growth Factor Binding Protein-3, Transforming Growth Factor β, Soluble Fas, and Superoxide Dismutase Activity for the JACC Study , 2005, Journal of epidemiology.

[5]  E. Benjamin,et al.  Obesity and Systemic Oxidative Stress: Clinical Correlates of Oxidative Stress in The Framingham Study , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[6]  D. Harrison,et al.  Role of oxidative stress in atherosclerosis. , 2003, The American journal of cardiology.

[7]  N. Yoshiike,et al.  Twenty‐year changes in the prevalence of overweight in Japanese adults: The National Nutrition Survey 1976–95 , 2002, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[8]  I. Sirois,et al.  Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  I. Sirois,et al.  Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  Y Ohno,et al.  Japan collaborative cohort study for evaluation of cancer risk sponsored by monbusho (JACC study). , 2001, Journal of epidemiology.

[11]  L. Owen-Schaub,et al.  Fas and Fas ligand interactions in malignant disease. , 2000, International journal of oncology.

[12]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[13]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.